Cellectis Company Profile, Contacts & Intelligence

Biotechnology ResearchParis, Fr237 employeesCLLSFounded 1999
3 contacts with email or phone data3 with email data1 with phone data
Employees
237
Company source estimate
Reachable Contacts
3
Visible contacts with email or phone data
Contacts With Email
3
3 of 4 visible contacts
Departments
6
Mapped contact coverage

Cellectis Overview

Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs. With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells. Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC. We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases. At Cellectis, we are committed to a cure. Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/ Follow our other social media account on X. (*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123. TALEN® is a registered trademark owned by the Cellectis Group.

Headquarters
Paris, Fr
Industry
Biotechnology Research
Founded
1999
Stock Symbol
CLLS
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Phone Number
Available in AeroLeads
Company Email
Available in AeroLeads

Cellectis Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

3 contacts with contact data
3 with email data and 1 with phone data in the visible sample.
6 departments represented
Visible contacts with email or phone data are mapped to these departments.
13 company-domain emails
Visible contacts using Cellectis's company email domain.
General
7
IT
3
Executive
2
Finance
2
Legal
1
Operations
1

Cellectis People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Cellectis Workforce Composition

Seniority breakdown across 25 visible profiles.

Manager
10
Individual contributor
9
Director
3
Senior / Lead
2
VP / Head
1

Cellectis Technology & Talent

Technology-related job titles represented in the visible people data.

Engineering
5
Data / AI
1

Compare Similar Companies to Cellectis

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
Transgene Biotechnology 212 View company
GENFIT Biotechnology 208 View company
Innate Pharma Biotechnology Research 198 View company
Nanobiotix Nanotechnology Research 149 View company
BIOASTER Biotechnology Research 106 View company
Abivax Biotechnology 89 View company
MaaT Pharma Biotechnology Research 85 View company
OSE Immunotherapeutics Biotechnology Research 82 View company
PHAXIAM Therapeutics Biotechnology 72 View company
Enterome Biotechnology Research 42 View company